Edgewise Therapeutics announced positive topline data from its Phase 1 and 2 trials of EDG-7500 for obstructive hypertrophic cardiomyopathy (HCM). The drug demonstrated significant reductions in left ventricular outflow tract pressure gradient (LVOT-G) and NT-proBNP levels, a key biomarker for heart failure, with a favorable safety profile.
Workday, Inc. (WDAY) is set to release its second-quarter fiscal 2025 earnings on August 22, after the closing bell. The company is expected to report higher revenues driven by strong demand for its human capital management (HCM) and financial management solutions. Key factors driving growth include the success of the Workday Government Cloud, strategic partnerships with Google and Salesforce, and a growing customer base.
